. 2024 Apr 10;20(22):1587–1600. doi: 10.2217/fon-2023-0301

Table 1.

Study characteristics of included trials.

Trial ID	Phase	Masking	Disease stage	Multicenter	Treatment	Follow-up duration, months, median (IQR)	Ref.
Alliance (CALGB 40502)	II	Open label	Stage IIIC-IV locally recurrent or metastatic	Yes	Paclitaxel ± bevacizumab	–	[19,20]
					Nab-paclitaxel ± bevacizumab
					Ixabepilone ± bevacizumab
E2100	III	Open label	Stage IV metastatic	Yes	Paclitaxel ± bevacizumab	41.6 (–)^‡	[21]
E2100	III	Open label	Stage IV metastatic	Yes	Paclitaxel	43.5 (–)^‡
IMpassion130	III	Double blind	Metastatic or unresectable locally advanced	Yes	Atezolizumab ± nab-paclitaxel	18.8 (8.9–34.7)	[22–27]
IMpassion130	III	Double blind	Metastatic or unresectable locally advanced	Yes	Placebo ± nab-paclitaxel	18.8 (8.9–34.7)
JapicCTI-090921	III	Open label	Metastatic or unresectable locally advanced	Yes	Nab-paclitaxel	23 (–)^‡	[28]
JapicCTI-090921	III	Open label	Metastatic or unresectable locally advanced	Yes	Docetaxel	23 (–)^‡
KEYNOTE-355	III	Double blind	Locally recurrent or metastatic	Yes	Pembrolizumab ± chemotherapy^†	25.9 (22.8–29.9)	[29–32]
KEYNOTE-355	III	Double blind	Locally recurrent or metastatic	Yes	Chemotherapy^†	26.3 (22.7–29.7)
MERiDiAN	III	Double blind	Metastatic	Yes	Placebo ± paclitaxel	14.8 (–)^‡	[33]
MERiDiAN	III	Double blind	Metastatic	Yes	Bevacizumab ± paclitaxel	15.0 (–)^‡
tnAcity	II/III	Open label	Locally advanced inoperable or metastatic	Yes	Nab-paclitaxel ± carboplatin	–	[34]
					Nab-paclitaxel ± gemcitabine
					Gemcitabine ± carboplatin
TNT	II	Open label	Metastatic	Yes	Carboplatin	–	[35]
TNT	II	Open label	Metastatic	Yes	Docetaxel	–

^†

Nab-paclitaxel, paclitaxel or gemcitabine/carboplatin.

^‡

Follow-up for duration for entire trial population, including non-TNBC patients.

*Intervention not of interest.

IQR: Interquartile range; TNBC: Triple-negative breast cancer.